Cargando…
A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma()
A deepened understanding of the cellular and molecular processes in the tumor microenvironment is necessary for the development of precision immunotherapy (IT). We simultaneously investigated CD3, PDL1, and IDO by immunohistochemistry in paired biopsies from various organs of 43 metastatic melanoma...
Autores principales: | Krähenbühl, Lukas, Goldinger, Simone M, Mangana, Joanna, Kerl, Katrin, Chevolet, Ines, Brochez, Liève, Horak, Christine, Levesque, Mitch, Dummer, Reinhard, Cheng, Phil F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767907/ https://www.ncbi.nlm.nih.gov/pubmed/29331888 http://dx.doi.org/10.1016/j.neo.2017.12.002 |
Ejemplares similares
-
Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma
por: Brochez, Lieve, et al.
Publicado: (2018) -
Impact of Covid-19 on the management of patients with metastatic melanoma
por: Welti, Michèle, et al.
Publicado: (2022) -
Addendum: Impact of Covid-19 on the management of patients with metastatic melanoma
por: Welti, Michèle, et al.
Publicado: (2023) -
IDO Expression in Cancer: Different Compartment, Different Functionality?
por: Meireson, Annabel, et al.
Publicado: (2020) -
Long-term pegylated interferon-α and its potential in the treatment of melanoma
por: Dummer, Reinhard, et al.
Publicado: (2009)